NCT05028322 (IDMODVHB) is a Phase 2 clinical trial of IMIQUIMOD cream in Cirrhosis, Liver, sponsored by Central Hospital, Nancy, France.

Who is sponsoring NCT05028322?

NCT05028322 is sponsored by Central Hospital, Nancy, France.

What drugs are being tested in NCT05028322?

Interventions in NCT05028322: IMIQUIMOD cream, HEPATITIS B SURFACE ANTIGEN.

What condition does NCT05028322 study?

NCT05028322 studies Cirrhosis, Liver, Vaccination Failure, HBV, Vaccine Reaction.

Is NCT05028322 still recruiting?

NCT05028322 is currently status unknown. Last updated 31 August 2021.

Last reviewed 2021-08-31 · How we verify

NCT05028322: IDMODVHB

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Intradermal Hepatitis B Vaccine After IMIQUIMOD's Application, in Cirrhotics Who Did Not Respond to the Usual Vaccine Regimen

Status unknown Phase 2 Last updated 31 August 2021

What this trial tests

Phase 2 trial testing IMIQUIMOD cream in Cirrhosis, Liver in 60 participants. Status unknown.

Timeline

1 November 2021

Primary endpoint
1 December 2024

1 December 2024

Quick facts

Lead sponsor	Central Hospital, Nancy, France
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	60
Start date	1 November 2021
Primary completion	1 December 2024
Estimated completion	1 December 2024

Drugs / interventions tested

IMIQUIMOD cream
HEPATITIS B SURFACE ANTIGEN — full drug profile →

Conditions studied

Cirrhosis, Liver — all drugs for Cirrhosis, Liver →
Vaccination Failure — all drugs for Vaccination Failure →
HBV — all drugs for HBV →
Vaccine Reaction — all drugs for Vaccine Reaction →

Sponsor

Central Hospital, Nancy, France

Who can join

18 and older, any sex, with Cirrhosis, Liver or Vaccination Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In a population of cirrhotics patients who did not responde to an anti-HBV vaccination according to the recommended vaccination, the goal is to : Describe the proportion of patients with HBs antibody levels greater than 10mUI/mL at 1 month of the last injection of vaccine ; with a M0-M1-M6 vaccine regimen using 3 vaccines strategies : * After simple intramuscular vaccine (IM) ( Control group ) * After simple intradermal vaccine * after IMIQUIMOD's application followed by intradermal vaccine administration The main hypothesis of this study is : IMIQUIMOD acts as an immunity booster, so the combination of IMIQUIMOD with an intra-dermal injection of the anti-HBV vaccine allows better acquisition of post-vaccination immunization.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Recent Advances in the Development of Toll-like Receptor Agonist-Based Vaccine Adjuvants for Infectious Diseases.
Yang JX, Tseng JC, Yu GY, Luo Y, et al · · 2022 · cited 81× · PMID 35214155 · DOI 10.3390/pharmaceutics14020423
Pattern recognition receptors: function, regulation and therapeutic potential.
Chen R, Zou J, Chen J, Zhong X, et al · · 2025 · cited 53× · PMID 40640149 · DOI 10.1038/s41392-025-02264-1

Verify or expand the search:

Other recruiting trials for Cirrhosis, Liver

Currently open trials in the same condition.

NCT07286643 — Echocardiography-guided Cirrhosis and Liver Failure-Intensive Care Protocol Sepsis · NA · recruiting
NCT06871111 — The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial · Phase 1 · recruiting
NCT07122700 — Evaluation of Non-Invasive Tests for Metabolic Liver Disease · recruiting
NCT07051369 — Frequency of Portal Hypertension Among Patient With Cirrhotic Liver With Ultrasound · active not recruiting
NCT06908785 — Utility of ROTEM® for Risk Stratification of Post-Invasive Procedure Hemorrhage in Patients With Cirrhosis (CIR-ROTEM) · recruiting

Other Central Hospital, Nancy, France trials

Trials by the same sponsor.

NCT06452290 — PET Biomarker Study for Antidepressant Response Prediction in Major Depressive Disorder · NA · not yet recruiting
NCT07518498 — Hypnosis During Mechanical Ventilation Weaning · NA · not yet recruiting
NCT07471334 — Prospective Study of Postictal Psychotic Symptoms Occuring After Video-EEG Monitoring in Focal Epilepsies · NA · not yet recruiting
NCT07414667 — Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification ( · not yet recruiting
NCT07415759 — Imaging of Electrical Properties by MRI: Investigation of Age-Related Changes · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05028322 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Central Hospital, Nancy, France
Last refreshed: 31 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05028322.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing